Pic for Estro Cropped
VasoDynamics Presents Phase-1b NG11-2 Clinical Data at ESTRO Conference

At the recent ESTRO conference in Glasgow on 3-7 May 2024, VasoDynamics presented the preliminary findings from its Phase-1b Study with NG11-2.

9th May 2024 VasoDynamics Ltd, the pharmaceutical company developing therapies for the prevention of the debilitating side-effects of cancer treatment, has presented the preliminary data on its phase-1b study. This study is investigating the safety and preliminary efficacy of NG11-2 in the prevention of severe Radiation induced Oral Mucositis (RIOM) in Head & Neck cancer patients undergoing radiotherapy. Severe RIOM is a debilitating side effect for patients undergoing radiotherapy, yet to date there are no approved pharmaceutical products with clinically meaningful efficacy to prevent it.

Ningfeng Fiona Li, CEO of VasoDynamics, said:

“We are excited to present the preliminary data from our first clinical study in UK which suggests that the NG11-2 mouthwash treatment is well tolerated and has a promising readout on protecting the oral mucosa in patients undergoing radiotherapy for their Head and Neck Cancer. The full study results are expected in early Q4 this year.”

European Society for Radiotherapy and Oncology (ESTRO)

The European Society for Radiotherapy and Oncology (ESTRO) is a non-profit and scientific organisation that advances all aspects of radiation oncology in order to improve patients’ care in the multimodality treatment of cancer. ESTRO’s mission is to promote best practice, research and dissemination of science through its special meetings, educational courses and publications. With over 6,500 members in and outside Europe, ESTRO supports all the radiation oncology professionals in their daily practice: radiation oncologists, medical physicists, radiobiologists and radiation therapists (RTTs) and the wider oncology community.

For enquiries, please contact:

Dr Ningfeng Fiona Li, CEO +44 7969132263
fiona.li@vasodynamics.co.uk
Gary Bower, COO +44 7960388412
gary.bower@vasodynamics.co.uk

Notes to Editors:

About VasoDynamics

VasoDynamics is a pharmaceutical development company based in Stevenage-London, UK. It is a clinical stage biopharma company with experienced and culture-diversified executives who have shared vision to improve the standard of cancer care globally. Recognising the mounting cost pressures facing healthcare payers all over the world, the company is developing a number of cost-effective medicines, all of which target the prevention of debilitating and often dose-limiting complications of cancer therapy, such as chemotherapy and radiotherapy induced mucositis, dermatitis, and hair-loss. We take great pride in our culture of scientific and development rigour, and our programmes are based on scientific finding and innovations from world-leading research bodies. The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculatures developing a serials of pipeline products for various types of cancer patient cohorts, hence to achieve the most effective and patient friendly protections to prevent severe side-effects during various types of cancer treatments.